Last reviewed · How we verify
NCT06686953
The Effect of Environmental Pollution on Colorectal Cancer
trial in Colorectal Carcinoma in 6,300 participants. Completed in 1 November 2024.
1 November 2024
Quick facts
| Lead sponsor | Dong Peng |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 6,300 |
| Start date | 1 January 2010 |
| Primary completion | 1 November 2024 |
| Estimated completion | 1 November 2024 |
Conditions studied
- Colorectal Carcinoma — all drugs for Colorectal Carcinoma →
Sponsor
Dong Peng
Who can join
18 and older, any sex, with Colorectal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Colorectal cancer (CRC) is one of the most common malignancies worldwide, and its main risk factors include age, genetic factors, inflammatory bowel diseases (e.g., ulcerative colitis and Crohn's disease), unhealthy diets (e.g., high-fat, low-fibre diets), obesity, physical inactivity, smoking, and excessive alcohol consumption. The relationship between environmental pollution and colorectal cancer has received increasing attention in recent years. Studies have shown that long-term exposure to fine particulate matter in the air, such as passive smoking, soot and oil smoke exposure, incense burning exposure, occupational exposure and outdoor work, PM2.5, PM10 and NO2 may increase the risk of colorectal cancer. These particulate matter can enter the lungs through breathing and trigger a chronic inflammatory response in the systemic system, thus increasing the risk of cancer development. This study intends to determine the extent of air pollution's impact on colorectal cancer prognosis by analysing survival data of colorectal cancer patients in regions with different pollution levels. As well as to investigate the association between air pollution levels and postoperative recurrence in colorectal cancer patients, looking for possible mechanisms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06686953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Carcinoma
Currently open trials in the same condition.
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06557733 — An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis · Phase 2 · recruiting
- NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07192068 — Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration · Phase 2 · recruiting
Other Dong Peng trials
Trials by the same sponsor.
- NCT07126743 — Organic Pollutant Build-Up in Body Fat and Stomach Tissue Linked to Obesity Levels · active not recruiting
- NCT07063550 — Microplastics in Paraneoplastic and Intratumoral for Colorectal Cancer · active not recruiting
- NCT06856382 — The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer · active not recruiting
- NCT06854146 — The Effect of Environmental Factors on Gastric Cancer Based on Macrogenome · active not recruiting
- NCT06852495 — the Effect of Environmental Factors on Colorectal Cancer Based on Macrogenomes · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06686953 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dong Peng
- Last refreshed: 13 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06686953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing